MET and non-small cell lung carcinoma: In addition to EGFR and ALK alterations, a spectrum of less common oncogenic drivers has been identified in NSCLC, including ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, KRAS G12C, and HER2 mutations (Table 2) [24].